CORRECTING and REPLACINGKATE, Japan’s No. 1 Makeup Brand, Launches Strategic Initiatives to Strengthen Business and Brand Recognition Across Asia
4.6.2025 07:10:00 CEST | Business Wire | Press release
Promoting Japanese Makeup Culture Globally and Enhancing Regional Presence
Seventh paragraph, first sentence of release dated June 3, 2025, at 10:10 p.m. PT/June 4, 2025, at 1:10 a.m. ET, should read:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603453681/en/

An image post of the Collaboration by KATE, with JUJUTSU KAISEN
Under the campaign slogan “Makeup is the most powerful technique to control your confidence”, the collaboration highlights the transformative potential and creative possibilities of makeup on a global scale.
Please also replace the second image with the accompanying corrected image.
The updated release reads:
KATE, JAPAN’S NO. 1 MAKEUP BRAND, LAUNCHES STRATEGIC INITIATIVES TO STRENGTHEN BUSINESS AND BRAND RECOGNITION ACROSS ASIA
Promoting Japanese Makeup Culture Globally and Enhancing Regional Presence
Kao Corporation (TOKYO:4452) has identified its international makeup brand KATE as a strategic growth driver within its cosmetics portfolio. This initiative aligns with the company’s ambition to establish a “Global Sharp Top” business framework. In line with this vision, Kao is making significant investments to amplify KATE’s global presence.
As part of this initiative, KATE will broaden the reach of its signature “Shadow Enhancing Makeup” philosophy—a technique deeply inspired by Japan’s cultural appreciation for shadows and light. In its role as Japan’s No.1 makeup brand*1, KATE will also collaborate with iconic Japanese cultural content to showcase the richness of both Japanese makeup culture and the broader essence of Japanese heritage on the global stage.
To enhance the brand’s value, KATE will elevate the experience at its global flagship store KATE TOKYO Shibuya Sakura Stage, through immersive UX experiences. This strategic move aims to accelerate global growth, particularly across Asia.
Brand Expansion Strategy in Asia
Since its launch in 1997, KATE has championed the slogan “NO MORE RULES.” empowering individuals to express their personality and confidence through makeup, unbound by trends or convention. Recognized for pioneering the shadow enhancing makeup technique, KATE creates striking facial dimension and expression through the interplay of light and shadow.
KATE has established itself as Japan’s No.1 makeup brand*1 and has played a significant role in evolving Japanese makeup culture. The brand is now expanding its signature makeup technique to consumers across Asia, where makeup culture shares many similarities with Japan, and where eye makeup plays a pivotal role. As a distinguished ambassador of Japanese makeup culture, the brand aims to transcend borders while continuing to inspire individuality and confidence in its consumers.
*1 Survey by INTAGE SRI+: Cumulative sales amount in the makeup market from January 2021 to December 2024
June: Collaboration with Popular Anime “JUJUTSU KAISEN Hidden Inventory / Premature Death” *2
Beginning June 2, KATE is excited to unveil a limited-edition collaboration with the globally acclaimed comic-turned anime series JUJUTSU KAISEN. Known for its commitment to breaking conventions and fostering creative self-expression through meticulously designed products, KATE aims to inspire users to unleash their creativity. This collaboration introduces a collection of limited-edition products featuring packaging designs inspired by striking scenes that highlight the intense gaze of the iconic character Satoru Gojo. The collection will be available from June 21.
Under the campaign slogan “Makeup is the most powerful technique to control your confidence”, the collaboration highlights the transformative potential and creative possibilities of makeup on a global scale. To support the campaign, a dedicated photo spot featuring Satoru Gojo will be installed at the brand’s flagship store, KATE TOKYO Shibuya Sakura Stage. Additionally, a special microsite will be launched on KATE’s official website. The campaign will leverage a comprehensive “OMO (Online Merges with Offline)” strategy, seamlessly integrating social media platforms such as X, Instagram, and TikTok with in-store experiences and campaign video content, maximizing user interaction and engagement.
Limited-Edition JUJUTSU KAISEN Collaboration Product Lineup
Product Name | Variants | Suggested Retail Price |
KATE Designing Eyebrow 3D | 2 types | JPY 1,100 (incl. tax: JPY1,210) |
KATE Super Sharp Liner EX4.0 | 2 types | JPY 1,300 (incl. tax: JPY 1,430) |
For more information, visit the JUJUTSU KAISEN collaboration microsite. | ||
*2 © Gege Akutami / Shueisha, JUJUTSU KAISEN Project
July: “LIGHTS ON SHADOW.” Collaboration with renowned Japanese artists
In July, KATE is set to launch a collaboration with renowned Japanese artists popular throughout Asia. Centered on the theme “Shadow Enhancing Makeup Transcends Dimensions”, this campaign illustrates how the expert application of highlights and shadows can evoke stunning beauty that bridges the two- and three-dimensional realms.
In addition to product offerings, including eyeshadow and eyebrow items designed for shading techniques, the campaign will symbolically portray the process of unlocking one’s individuality and gaining confidence through hyper-realistic visual techniques. Local brand ambassadors will be appointed in key Asian markets such as Taiwan and Thailand to amplify the cultural narrative and reach of Japanese makeup artistry.
September: Jointly developed with Universal Studios Japan, a next-generation walkthrough attraction
On September 5, KATE will unveil a collaboration with Universal Studios Japan, a popular destination for both local and international visitors. Together, they will co-create a new attraction:
“Witches of House 18: Bewitching Mansion of Emotion”, as part of the park’s Halloween Horror Nights event.
This marks the first-ever co-development of an attraction between Universal Studios Japan and an official event partner. Centered on the theme “Unleash the self hidden inside you”, the experience draws out a wide range of emotions through the guidance of four witches, revealing new dimensions of the self. This collaboration between KATE and Universal Studios Japan delivers a one-of-a-kind experience, unlocking extraordinary surprises and creative freedom that empower guests to express their best selves.
KATE will continue to promote Japanese makeup culture throughout Asia by engaging in ongoing media outreach and creating unique consumer experiences. With the goal of becoming Asia’s No.1 makeup brand, Kao is dedicated to enhancing KATE’s market presence as part of its broader strategy to build a “Global Sharp Top” cosmetics portfolio.
Related Information
KATE Official Brand Website
KATE unveils first global flagship store (Press release from July 2024)
JUJUTSU KAISEN Official TV Anime Website
Universal Studios Japan Official Website
KATE is the official event partner of Universal Studios Japan.
HARRY POTTER and all related characters and elements © & ™ Warner Bros. Entertainment Inc. Publishing Rights © J.K. Rowling.
MINIONS TM & © 2025 Universal Studios.
© Nintendo
TM & © Universal Studios & Amblin Entertainment
TM & © 2025 Universal Studios. All rights reserved. CR25-1897
About Kao
Kao, a Japan-based manufacturer of personal care and household products, cosmetics, and specialty chemicals creates high-value-added products and services that provide care and enrichment for the life of all people and the planet. Through its brands such as Attack laundry detergent, Bioré and Jergens skin care products, Laurier sanitary products, Curél, SENSAI, and MOLTON BROWN cosmetics, and Oribe hair care products, Kao is part of the everyday lives of people across Asia, the Americas, Europe, the Middle East, and Africa. Combined with its chemical business, which contributes to a wide range of industries, Kao generates about 1,630 billion yen in annual sales. Kao employs about 32,600 people worldwide and has more than 130 years of history in innovation. As an enterprise that provides products people use on a daily basis, the Kao Group takes responsibility to actively reduce the environmental footprint of its products throughout the product lifecycle. This is laid out in Kao’s ESG strategy, the Kirei Lifestyle Plan, which launched in 2019.
Please visit the Kao Group website for additional information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250603453681/en/



Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom